FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2246301092> ?p ?o ?g. }

• W2246301092 abstract "The first purpose of the present dissertation was to apply a high throughput assay to systematically screen a library of food and drug administration (FDA)-approved drugs as potential ligands for the cannabinoid receptor 2 (CB2). A cell-based, homogenous time resolved fluorescence (HTRF) method for measuring changes in intracellular cAMP levels was validated and found to be suitable for testing ligands that may act on CB2. Among the 640 FDA-approved drugs screened, raloxifene, a drug used to treat/prevent post-menopausal osteoporosis, was identified for the first time to be a novel CB2 inverse agonist. The dissertation reporting these results demonstrated that by acting on CB2, raloxifene enhances forskolin-stimulated cAMP accumulation in a concentration-dependent manner. Furthermore, the data showed that raloxifene competes concentration-dependently for specific [3H]CP-55,940 binding to CB2. In addition, raloxifene pretreatment caused a rightward shift of the concentration-response curves of the cannabinoid agonists CP-55,940, HU-210, and WIN55,212-2. Raloxifene antagonism is vi most likely competitive in nature, as these rightward shifts were parallel and were not associated with any changes in the efficacy of cannabinoid agonists on CB2. The discovery that raloxifene is as an inverse agonist for CB2 suggests that it might be possible to repurpose this FDA-approved drug for novel therapeutic indications for which CB2 is a target. Furthermore, identifying raloxifene as a CB2 inverse agonist also provides important novel mechanisms of actions to explain the known therapeutic effects of raloxifene. The second purpose of the current study was to investigate the ability of the third-generation selective estrogen receptor modulators (SERMs) bazedoxifene and lasofoxifene to bind and act on CB2 cannabinoid receptor. We have identified, for the first time, that CB2 is a novel target for bazedoxifene and lasofoxifene. Our results showed that bazedoxifene and lasofoxifene were able to compete for specific [3H]CP-55,940 binding to CB2 in a concentration-dependent manner. Our data also demonstrated that by acting on CB2, bazedoxifene and lasofoxifene concentration-dependently enhanced forskolin-stimulated cAMP accumulation. Furthermore, bazedoxifene and lasofoxifene caused parallel, rightward shifts of the CP-55,940, HU-210, and WIN55,212-2 concentration-response curves without altering the efficacy of these cannabinoid agonists on CB2, which indicates that bazedoxifene- and lasofoxifene-induced CB2 antagonism is most likely competitive in nature. Our discovery that CB2 is a novel target for bazedoxifene and lasofoxifene suggests that these third-generation SERMs can potentially be repurposed for novel therapeutic indications for which CB2 is a target. In addition, identifying bazedoxifene and lasofoxifene as CB2 inverse agonists also provides important novel mechanisms of actions to explain the known therapeutic effects of these SERMs. The third purpose of this dissertation was to investigate the structure-activity relationships of fatty acid amides for activating and desensitizing G protein-coupled receptor 119, a promising therapeutic target for both type 2 diabetes and obesity. Using novel fatty acid amides and detailed potency and efficacy analyses, the dissertation reporting these results demonstrated that degree of saturation in acyl chain and charged head groups of fatty acid amides have profound effects on the ability of these compounds to activate G protein-coupled receptor 119. In addition, the dissertation reporting these results demonstrated for the first time that pretreatments with G protein-coupled receptor 119 agonists desensitize the receptor and the degrees of desensitization caused by fatty acid amides correlate well with their structure-activity relationships in activating the receptor. The fourth purpose of this dissertation was to use a fragment-based approach, categorical-SAR (cat-SAR), to model ligands for GPR119. Using compounds that are known GPR119 agonists and compounds that were confirmed experimentally that are not GPR119 agonists, four distinct cat-SAR models were developed. Using a leave-one out validation routine, the best GPR119 model had an overall concordance of 99 %, a sensitivity of 99 %, and a specificity of 100 %. The dissertation reporting these results from the in-depth fragment analysis of several known GPR119 agonists was consistent with previously reported GPR119 structure-activity relationship (SAR) analyses. Overall, while the dissertation reporting these results indicates the development a highly predictive cat-SAR model that can be potentially used to rapidly screen for prospective GPR119 ligands the applicability domain must be taken into consideration. Moreover, the dissertation demonstrating these results was the first report that the cat-SAR expert system can be used to model G protein-coupled receptor ligands, many of which are important therapeutic agents." @default.
• W2246301092 created "2016-06-24" @default.
• W2246301092 creator A5059087272 @default.
• W2246301092 date "2016-02-22" @default.
• W2246301092 modified "2023-09-27" @default.
• W2246301092 title "Searching for novel ligands for the cannabinoid and related receptors." @default.
• W2246301092 cites W1510592624 @default.
• W2246301092 cites W1518589347 @default.
• W2246301092 cites W1525602924 @default.
• W2246301092 cites W1560863505 @default.
• W2246301092 cites W1564473377 @default.
• W2246301092 cites W1582296909 @default.
• W2246301092 cites W1591647183 @default.
• W2246301092 cites W1670633125 @default.
• W2246301092 cites W16953059 @default.
• W2246301092 cites W1812356957 @default.
• W2246301092 cites W1824285398 @default.
• W2246301092 cites W1826575181 @default.
• W2246301092 cites W1832918544 @default.
• W2246301092 cites W1844090762 @default.
• W2246301092 cites W1911828734 @default.
• W2246301092 cites W1943648506 @default.
• W2246301092 cites W1968926131 @default.
• W2246301092 cites W1971909806 @default.
• W2246301092 cites W1976389084 @default.
• W2246301092 cites W1976890130 @default.
• W2246301092 cites W1977929532 @default.
• W2246301092 cites W1978636433 @default.
• W2246301092 cites W1979392240 @default.
• W2246301092 cites W1982186440 @default.
• W2246301092 cites W1983466821 @default.
• W2246301092 cites W1989073099 @default.
• W2246301092 cites W1991001144 @default.
• W2246301092 cites W1992756923 @default.
• W2246301092 cites W1995208376 @default.
• W2246301092 cites W1998165103 @default.
• W2246301092 cites W2005295755 @default.
• W2246301092 cites W2006954988 @default.
• W2246301092 cites W2010947724 @default.
• W2246301092 cites W2011161535 @default.
• W2246301092 cites W2018953051 @default.
• W2246301092 cites W2024653583 @default.
• W2246301092 cites W2026687408 @default.
• W2246301092 cites W2032178587 @default.
• W2246301092 cites W2035086154 @default.
• W2246301092 cites W2036099492 @default.
• W2246301092 cites W2036805527 @default.
• W2246301092 cites W2038284855 @default.
• W2246301092 cites W2039654095 @default.
• W2246301092 cites W2039666288 @default.
• W2246301092 cites W2041444093 @default.
• W2246301092 cites W2041624484 @default.
• W2246301092 cites W2042142307 @default.
• W2246301092 cites W2042676931 @default.
• W2246301092 cites W2042914433 @default.
• W2246301092 cites W2043594482 @default.
• W2246301092 cites W2044281547 @default.
• W2246301092 cites W2046672585 @default.
• W2246301092 cites W2048636541 @default.
• W2246301092 cites W2051521999 @default.
• W2246301092 cites W2053196978 @default.
• W2246301092 cites W2054250221 @default.
• W2246301092 cites W2054935554 @default.
• W2246301092 cites W2056188558 @default.
• W2246301092 cites W2056966948 @default.
• W2246301092 cites W2057054987 @default.
• W2246301092 cites W2057882975 @default.
• W2246301092 cites W2059543009 @default.
• W2246301092 cites W2059977407 @default.
• W2246301092 cites W2061345986 @default.
• W2246301092 cites W2063388729 @default.
• W2246301092 cites W2069971273 @default.
• W2246301092 cites W2072759829 @default.
• W2246301092 cites W2073113196 @default.
• W2246301092 cites W2074086013 @default.
• W2246301092 cites W2075894678 @default.
• W2246301092 cites W2076025331 @default.
• W2246301092 cites W2078434336 @default.
• W2246301092 cites W2079052124 @default.
• W2246301092 cites W2083371696 @default.
• W2246301092 cites W2084948079 @default.
• W2246301092 cites W2085004926 @default.
• W2246301092 cites W2085418154 @default.
• W2246301092 cites W2092017792 @default.
• W2246301092 cites W2095903335 @default.
• W2246301092 cites W2096726403 @default.
• W2246301092 cites W2097054866 @default.
• W2246301092 cites W2098730433 @default.
• W2246301092 cites W2098889553 @default.
• W2246301092 cites W2100587870 @default.
• W2246301092 cites W2103829266 @default.
• W2246301092 cites W2117464417 @default.
• W2246301092 cites W2121175754 @default.
• W2246301092 cites W2127160263 @default.
• W2246301092 cites W2129347432 @default.
• W2246301092 cites W2130462726 @default.
• W2246301092 cites W2131899215 @default.
• W2246301092 cites W2133325086 @default.
• W2246301092 cites W2135686539 @default.
• W2246301092 cites W2138437384 @default.

• next